

## Dementia Antipsychotic Prescribing Guide Dosing, Special Populations

### Dosing

**Timing:** Usually once daily at night or prior to sundowning. Beware of sedation-related adverse events if given earlier than bedtime.

	Starting Dose (mg/day)	Max Dose for Maintenance* (mg/day)	Special Dosage Forms**
<b>Aripiprazole</b>	2-5	10	ODT, L, IM
<b>Haloperidol</b>	0.25	2	L, IM
<b>Olanzapine</b>	2.5-5	7.5	ODT, L, IM
<b>Quetiapine</b>	12.5-25	150	XR
<b>Risperidone</b>	0.25-0.5	2	ODT, L

\*per CMS regulations for long-term care facilities. Doses for acute treatment sometimes exceed maintenance doses.

\*\*ODT = orally dissolving tablet, L = liquid, IM = short-acting intramuscular, XR = extended release.

#### Dosage forms:

- Regular tablets can be crushed and mixed with food if needed.
- IM antipsychotics used only in emergencies when oral is refused.
- Topical forms, e.g. compounded creams, not recommended. No evidence to guide proper dosing. Absorption is unknown and unpredictable.

### Guidance for Special Populations

**Frontotemporal dementia:** Some evidence for trazodone. Mixed for SSRIs. See Iowa Geriatric Education Center website for details.

#### Parkinson's disease (PD) and Lewy body dementia (LBD):

**-Movement disorder treatments** (dopamine agonists, carbidopa-levodopa, anticholinergics) can cause **psychosis or delirium**. Prior to antipsychotic use, consider reducing the dose of these drugs to see if the psychosis or behaviors resolve or become manageable.

-People with PD and LBD are **very sensitive to adverse effects**, particularly **movement side effects and neuroleptic malignant syndrome**. If antipsychotics are used, expert guidelines recommend **quetiapine or clozapine** due to lower movement side effect risk.

**Renal Impairment:** Reduce risperidone dose. Titrate slowly.

**Hepatic Impairment:** Possibly reduce dose of olanzapine, quetiapine, risperidone. Caution with all.

## Dementia Antipsychotic Prescribing Guide Monitoring for Response and Adverse Effects

### Monitoring for Response

**-Clearly document** treatment target symptoms. If the drug does not help, discontinue the drug. These symptoms may also change over time, with or without drug treatment.

**-Do not expect an immediate response.** Sedation may explain much of any immediate effect that is seen. Response may take 2-4 weeks.

**-Do not increase doses too quickly** if the patient doesn't respond right away. At a stable dose, drug blood levels may rise for several days to a week or more before reaching a steady state level.

**Increased doses lead to increased side effects.**

### Monitoring for Adverse Effects

Other possible adverse effects include: falls, constipation, urinary tract infection, urinary incontinence or retention, stroke, arrhythmias, and neuroleptic malignant syndrome.

Side Effect	Monitoring
<b>Movement Side Effects</b>	Observation for tremor, gait changes, difficulty swallowing, signs of parkinsonism, restlessness (akathisia), unusual movements (tardive dyskinesia).
	Abnormal Involuntary Movement Scale (AIMS) at baseline, every 6 months, or if movement side effects are suspected.
<b>Central Nervous System</b>	
<b>Sedation</b>	Observation, sedation scale if needed.
<b>Confusion, delirium, or other cognitive worsening</b>	Observation for mental status or behavior changes.
	Delirium screening tool, e.g. CAM (Confusion Assessment Method) if delirium is suspected.
<b>Psychotic symptoms</b>	Observation for worsening symptoms.
<b>Cardiovascular / Metabolic</b>	
<b>Orthostatic hypotension</b>	Observation for signs of dizziness or falls.
	Orthostatic blood pressure (if feasible). Monthly, or if signs of dizziness occur. More frequent on initiation or after dose increase.
<b>Edema</b>	Observation for swelling of extremities.
<b>Weight gain</b>	Monthly weight. Consider weekly for 1 month if overweight. Watch for increased appetite.
<b>Hyperglycemia / Diabetes</b>	Blood glucose at baseline, 3 & 6 months, then q6 months. Also PRN symptoms or mental status change. Monitor symptoms: increased thirst, urination, hunger, weakness.
<b>Triglyceride ↑</b>	Fasting blood lipid panel at baseline, 3 & 6 months, then q6 months. Especially if patient has cardiovascular risk factors: e.g. obesity, diabetes, hyperlipidemia.